Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Genetic and clinical factors best for predicting late recurrence in oestrogen receptor positive breast cancer

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.05.13
Views: 4997
Rating:

Dr Ivana Sestak - Queen Mary University of London, UK

ecancer reporter Peter Goodwin talks to Dr Sestak at the 2013 IMPAKT conference in Brussels about a new analysis which has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.

The ATAC trial included nearly 10,000 women who were treated with surgery followed by five years of treatment with the drugs anastrozole, tamoxifen or a combination of both. Of these 1,125 from the monotherapy arms (tamoxifen, anastrozole) were included in the transATAC study.

The five scores being compared were:

  • Clinical Treatment Score, which includes information on the patient’s disease and treatments so far;
  • IHC4 score, which characterises the presence of cell surface markers on cancer cells;
  • The Oncotype Dx Recurrence Score;
  • The PAM50 Risk of Recurrence Score;
  • The Breast Cancer Index score.

The results showed that the clinical treatment score alone was the best for predicting late recurrence, the researchers report. The components of this score include some that are already widely used by doctors, such as whether the cancer has spread to sentinel lymph nodes, the tumour size and grade.
Among the other tests, the PAM50 risk of recurrence score and the Breast Cancer Index score added the most significant prognostic value between years 5 and 10 after diagnosis.

 

ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation